The study does not provide near-term revenue catalysts but strengthens the differentiation narrative for acoramidis versus competitors (e.g., tafamidis). Monitor ESC Congress 2026 for additional CMR data. Approval and market access for Attruby are already established; this study supports label expansion and long-term value creation.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $79.37entry
- T+1 · 3mo ago −0.87%α −1.52% · $78.68
- T+5 · 3mo ago −3.62%α −3.50% · $76.50
- T+20 · 8w ago −16.49%α −16.72% · $66.28
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess long-term effects on cardiac structure, function, and amyloid burden. This builds on encouraging CMR substudy data from the Phase 3 ATTRibute-CM trial suggesting potential disease reversal. The study is prospective and open-label, enrolling ~150 patients with annual imaging over 36 months.
Key Facts
- First participant dosed in ASCEND-ATTR, a Phase 3b/4 open-label study of acoramidis in ATTR-CM
- Study will enroll ~150 participants with annual CMR and echocardiography over 36 months
- Primary endpoint: responder status at Month 36 by CMR based on improvement in LV systolic function
- Acoramidis is the only oral, near-complete (≥90%) TTR stabilizer approved (Attruby) for ATTR-CM
- Prior CMR substudy of ATTRibute-CM suggested improvement in LVMi, LVSVi, LVEF and evidence of amyloid regression
- Additional data from ATTRibute-CM CMR substudy and OLE to be shared at ESC Congress 2026
Financial Impact
Phase 3b/4 study initiation, no financial impact disclosed; acoramidis is already approved and commercialized for ATTR-CM
Risk Factors
- Single-arm, open-label design limits definitive conclusions versus placebo or active comparator
- Enrollment and 36-month follow-up timeline reduces near-term impact
- Risk that positive CMR substudy findings are not replicated in this larger, prospective study
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351235 |
Track record
38 reports on BBIO
10 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers